Guardant Health, Inc. (GH)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$43.10

P/E Ratio

N/A

Market Cap

$5.32B

Mar 19, 2024Apr 23, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$10.00$20.00$30.00$40.00$50.00
  • GH
Description
Add to research

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Metrics
Add to research

Overview

  • HQPalo Alto, CA
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerGH
  • Price$43.1+1.10%

Trading Information

  • Market cap$5.32B
  • Float95.61%
  • Average Daily Volume (1m)2,691,976
  • Average Daily Volume (3m)2,371,243
  • EPS-$3.56

Company

  • Revenue$739.02M
  • Rev growth (1yr)31.04%
  • Net income-$436.37M
  • Gross margin60.79%
  • EBITDA margin-54.29%
  • EBITDA-$401.21M
  • EV$4.25B
  • EV/Revenue5.75
  • P/EN/A
  • P/S7.16
  • P/BN/A
  • Debt/EquityN/A
Documents
Add to research